Lataa...
Focus on biosimilar etanercept – bioequivalence and interchangeability
BACKGROUND: The recent approval of reference etanercept (re-ETN) biosimilars SB4, GP2015, and HD203 produced relevant changes in the management of rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis due to the considerably lower cost of these products and the consequent saving...
Tallennettuna:
| Julkaisussa: | Biologics |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6121755/ https://ncbi.nlm.nih.gov/pubmed/30214149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S126854 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|